Clinical Trials Directory

Trials / Completed

CompletedNCT02467673

Nanoparticulate Versus Micronized Steroids Delivery for Transdermal Hormone Replacement Therapy

Nanoparticulate Versus Micronized Steroids Delivery for Transdermal Hormone Replacement Therapy: Effects on Blood Pressure, Insulin and C-reactive Protein and in Postmenopausal Women

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
185 (actual)
Sponsor
University Potiguar · Academic / Other
Sex
Female
Age
42 Years – 75 Years
Healthy volunteers
Accepted

Summary

The study aims to asses the effects of micronized (MIC) and nanoparticulate (NANO) transdermal hormone therapy (THT) on blood pressure, ultra-sensitive C-reactive protein (CRP), and cardiovascular risk factors in postmenopausal women.

Detailed description

In this open label study, 27 postmenopausal women, with no clinical evidence of cardiovascular disease, were randomly divided in two groups. During 12 weeks, 15 patients received on the left forearm micronized (MIC) THT (micronized 17β-estradiol 2.5 mg/day + progesterone 100 mg/day). and 14 patients received a nanoparticulate (NANO) THT (nanoparticulate 17β-estradiol 2.5 mg/day + progesterone 100mg/day). After 12 weeks of treatment patients were evaluated. Baseline and Post-THT measures were determined: Insulin, body mass index, waist circumference, blood pressure, CRP-stratified levels, total testosterone, TSH and FSH levels.

Conditions

Interventions

TypeNameDescription
DRUGMicronized estradiol + progesteroneAdministration of micronized estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
DRUGNanoparticulate estradiol + progesteroneAdministration of nanoparticulate estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.

Timeline

Start date
2012-01-01
Primary completion
2012-03-01
Completion
2012-07-01
First posted
2015-06-10
Last updated
2016-05-24

Locations

3 sites across 1 country: Brazil

Source: ClinicalTrials.gov record NCT02467673. Inclusion in this directory is not an endorsement.